Assessment of the Potential Risk of Cytochrome P450-Mediated Drug–Drug Interactions in Psychiatric Inpatients
Polypharmacy increases the risk of drug–drug interactions (DDIs) among patients with psychiatric disorders. Several psychiatric medications act as substrates, inhibitors, or inducers of cytochrome P450 (CYP), necessitating careful evaluation of CYP-mediated DDIs before administration. This study aimed to evaluate the potential risk of CYP-mediated DDIs among psychiatric inpatients.
Authors
- Kiyoto Kasai (ORCID: https://orcid.org/0000-0002-4443-4535)
- Tappei Takada (ORCID: https://orcid.org/0000-0002-3868-9320)
- Kayo Ichihashi (ORCID: https://orcid.org/0000-0003-0389-2617)
- Yoshiyuki Ohno (ORCID: https://orcid.org/0009-0005-4727-8792)
- Toyohito Oriyama (ORCID: https://orcid.org/0000-0002-0142-8709)
- Kota Imai
Institutions
- University of Tokyo Hospital (JP)
Publication Details
- Journal
- Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
- Published
- 2025-09-09
- DOI
- https://doi.org/10.5649/jjphcs.51.509
- Primary Topic
- Pharmaceutical Practices and Patient Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00